OR-RADISYS-CORPORATION
13.7.2021 14:02:07 CEST | Business Wire | Press release
Radisys® Corporation , a global leader of open telecom solutions, today introduced the Radisys Combo PON Optical Line Terminal (OLT) as part of the Radisys Connect Open Broadband portfolio for broadband service providers. The complete family of Radisys OLTs includes 16 and 32-port versions—a variant of which is the Radisys white box Combo PON OLT that supports both G-PON (2.488 Gbps downstream / 1.244 Gbps upstream) and XGS-PON (10 Gbps symmetrical) within the same PON port of the OLT. The white box OLTs are based on the VOLTHA/SEBA reference architecture and are field-hardened and scaled for commercial deployments today.
News Highlights
- A growing number of global service providers are moving forward with XGS-PON as their next-generation PON technology of choice. Analyst firm Dell-Oro Group predicts XGS-PON will be the favored PON technology for the future.
- Radisys’ Combo PON OLT allows broadband providers to take advantage of pervasive G-PON technology while giving them a flexible upgrade path to scale up and rollout XGS-PON deployments without costly rip and replace.
-
Radisys’ Combo PON OLT is an open, flexible, highly scalable telco-grade white box designed to address service providers’ key needs.
- Full PON port flexibility enables G-PON, XGS-PON or Combo PON (G-PON and XGS-PON) on any port on the same platform.
- Open architecture delivers datacenter-driven cost efficiencies and high port densities, making it suitable for residential, cloud and enterprise services to simplify deployments and reduce operating expenses.
- Compatibility with any ONF VOLTHA-based software, including Radisys’ Connect Broadband Access Controller (CBAC) software, allows service providers to scale hardware up or down while the management software and all other Connect Open Broadband components remain intact.
- Flexibility to deploy virtualized functions either in a distributed fashion running within the OLT CPU, or as a centralized function hosted on an external server or a public or private cloud.
- Radisys’ Combo PON OLTs are part of the Connect Open Broadband product suite, which includes open and disaggregated software, hardware and management.
- The complete family of Radisys OLTs also includes the 16 and 32-port OLTs. The Radisys 32 port G-PON OLT (RLT-3200G) was recently certified for VOLTHA v2.8 through Open Networking Foundation’s Continuous Certification Program.
“Radisys’ Combo PON OLTs give broadband providers an optimal economic advantage with the flexibility to use both G-PON and XGS-PON in their networks and through a reduction in space and power consumption,” said Harris Razak, senior vice president of Broadband Access, Radisys. “All products in the Connect Open Broadband portfolio utilize the same management system and controlling software, allowing our provider customers to choose the features and capacity they want while keeping other network elements the same, lowering their total cost of ownership and optimizing their Capex and Opex.”
“We are pleased that Radisys’ 32-port G-PON OLT has been named a certified VOLTHA product within the ONF Continuous Certification Program. This certification, along with the introduction of the Radisys Combo PON OLT with support for VOLTHA/SEBA, offers broadband service providers with greater solution choices for their FTTX deployments,” said Guru Parulkar, ONF Executive Director. “As an ONF Partner Member, Radisys has been instrumental in the development of ONF open reference designs as well as the commercialization of ONF-based solutions. The Continuous Certification Program ensures that service providers can easily identify certified products for specific ONF projects within a vibrant ecosystem of vendors delivering and deploying ONF open source platforms.”
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.Radisys.com .
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005445/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom